Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131378 · ClinicalTrials.gov registry record · NA
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 142
- Enrollment target
NCT00131378: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00131378 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131378, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body composition will be measured.
Primary Outcome
6 month change in HsCRP (primary cardiovascular risk endpoint)
Interventions
- DRUG Nutropin AQ growth hormone
- DRUG Placebo Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2004-11 |
| Est. Completion | 2013-06 |
| Phase | NA |
What the finished NCT00131378 record still lists
NCT00131378 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Nutropin AQ growth hormone is the first listed.
NCT00131378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00131378 about?
NCT00131378 is a clinical study titled "Growth Hormone, Cardiovascular Risk, and Visceral Adiposity". This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body compo...
What is the current status of trial NCT00131378?
This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2004-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00131378?
The interventions under investigation include: Nutropin AQ growth hormone (DRUG), Placebo Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT00131378?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00131378's enrollment target sits among peer trials
142 711th of 2000 higher than 1,289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia